RxDoctor Payments Data

Angela Kaptsan

Family · Wayland, MANPI 1528231461

Payments from drug & device makers

$1,765in general payments, 2019–2025

Across 19 payments — averaging $92.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$794
  • Tandem Diabetes Care, Inc.$298
  • Novo Nordisk$236
  • Lilly USA, LLC$215
  • Sanofi-aventis U.S. LLC$130
  • Cequr Corporation$72
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$1,765100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,765 in reported general payments places this provider in the 85th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$57,373
Medicare patients
219
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide238$347,507
TrulicityDulaglutide110$170,313
JardianceEmpagliflozin124$136,193
MounjaroTirzepatide109$129,465
JanuviaSitagliptin Phosphate103$97,054
TradjentaLinagliptin84$59,883
Tresiba Flextouch U-200Insulin Degludec43$58,880
Victoza 3-PakLiraglutide24$39,104
Fiasp FlextouchInsulin Aspart (Niacinamide)30$37,512
Tresiba Flextouch U-100Insulin Degludec56$31,922
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$30,795
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$26,035
Nano 2nd Gen Pen NeedlePen Needle, Diabetic188$25,106
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$23,185
Humalog Kwikpen U-100Insulin Lispro68$22,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$236$354,825251 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Lyumjev$215$310,152248 claims
Sanofi-aventis U.S. LLCLantus$130$1,31218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,320 family providers in Massachusetts.

Other family in Wayland

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →